Recent Updates
Recently added Catalysts

terbinafine hydrogen chloride

Phase 3

Onychomycosis | Small molecule | Other |Novartis AG|Last Updated: May 6, 2011

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment1,029
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00459537Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail OnychomycosisPHASE3 COMPLETED 1,029Mar 1, 2007Jan 1, 2009May 6, 201110 Finland, France +8
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percentage of Participants With Complete Cure at the End of Study After Treating Participants for 48 Weeks
Week 52

Complete cure is defined as negative potassium hydroxide (KOH) microscopy and negative culture for dermatophytes and no residual involvement of the target toenail.

Percentage of Participants With Complete Cure at the End of Study After Treating Participants for 48 Weeks.
Week 52

Complete cure is defined as negative potassium hydroxide (KOH) microscopy and negative culture for dermatophytes and no residual involvement of the target toenail.

Secondary Endpoints
Percentage of Participants With Clinical Effectiveness at the End of Study After Treating Patients for 48 Weeks.
Week 52
Percentage of Participants With Mycological Cure at End of Study After Treating Patients for 48 Weeks
Week 52
Safety and Tolerability Assessed by the Number of Participants With Adverse Events
Week 52
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
TerbinafineEXPERIMENTAL10% terbinafine hydrogen chloride (72.6 mg/ml nail lacquer). Patients applied one layer of the study medication once daily for 48 weeks, preferably at bedtime, to all affected toenails and allowed to dry.
AmorolfineACTIVE_COMPARATOR5% amorolfine nail lacquer. Patients applied study medication twice weekly for 48 weeks to all affected toenails.
Interventions
NameTypeDescription
terbinafine hydrogen chlorideDRUG10 % terbinafine hydrogen chloride (HCL)
amorolfine nail lacquerDRUG5 % amorolfine nail lacquer
Unlock Study Design Details
Eligibility Criteria
Age Range12 Years — 75 Years
SexALL
Healthy VolunteersNo
Study Sites10

Inclusion Criteria: * Male and females 12 - 75 years of age * Fungal toenail infection of one or both of the large (great) toenails * The nail infection must be due to a dermatophyte, (mixed infections \[dermatophyte and non-dermatophyte\] are not allowed) * The target toenail area must have at lea...

Countries:FinlandFranceGermanyHungaryIcelandNorwayPolandRussiaSpainTurkey (Türkiye)
Unlock Eligibility Criteria